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Whether or not the inclusion of incarcerated
individuals in clinical research studies is justified
has generated heated debate over the later part
of the past century. Some have advocated that
no research study can ethically include prison-
ers living in an inherently coercive environment,
while others counter that incarceration does not
strip an individual of his or her ability to make an
informed decision regarding participation as a
research subject.  
Much of this debate is fueled by the competing
concerns of protecting inmates as a vulnerable
population while respecting their individual
autonomy. This conflict is waged against the
backdrop of a historical legacy of unethical
treatment of incarcerated, institutionalized and
other vulnerable groups during clinical research
studies.
HISTORY OF RESEARCH IN PRISONS IN
THE TWENTIETH CENTURY
Research involving prisoners has had a trou-
bled past.  During the early part of the twentieth
century, there were well-documented instances
of investigators in the United States, and else-
where, using prison inmates to study the patho-
genesis, prevention, and treatment of a variety
of illnesses including cholera, beriberi, pellagra,
and tuberculosis.  Notorious experiments, such
as the transplantation or injection of human or
animal testicular material into senile men, were
conducted, and, although rare, reflected the
belief at the time that inmates were a population
that could be subjected to experimentation that
could not be performed on the general popula-
tion. The unique vulnerabilities of inmates in
these studies were often exploited. For exam-
ple, many of the participants were death row
inmates, some of whom died following injection
of cholera toxins or similarly dangerous proce-
dures.  "Volunteers" were recruited by promising
them clemency if they survived the experiment -
an incentive that today would be considered
highly coercive - while other participants
received special privileges or compensation
such as cigars or cigarettes.  Many inmates who
participated in studies during this period did not
give truly informed consent. Few understood
the risks and benefits, if any, of the research
protocols, and some may not have even been
asked to participate.1,2,3
The Second World War had a significant impact
on the inclusion of prisoners in research investi-
gations.  On the one hand, with the onset of the
war, investigators appealed to inmates to make
a patriotic contribution to the war effort by par-
ticipating in medical research that would assist
the military. The research included injections of
blood from cattle to investigate alternate
sources of blood products, studies of atropine
as an antidote, as well as experiments in which
subjects were infected with sleeping sickness,
dengue fever, gonorrhea, malaria, and agents of
gas gangrene.1,2,3
However, at the conclusion of World War II, the
discovery of human experimentation conducted
by the Nazis on those they had imprisoned led
to a wide scale re-evaluation of the ethics of
research of human subjects and the study of the
incarcerated in particular.  The Nuremberg War
Crime Tribunal was convened to investigate and
punish war time crimes perpetrated by the
Nazis, including hideous trials performed by the
Germans in concentration camps.  In 1947, the
tribunal produced the Nuremberg Code, a set of
10 basic tenets, which was drafted as the stan-
dard by which to judge physicians and scientists
during their trial at Nuremberg. It became an
ethical standard for research for decades.  
The first of these tenets, that "the voluntary con-
sent of the human subject is absolutely essen-
tial . . . . [and] should be so situated as to be
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able to exercise free power of choice with-
out  . . . the intervention of any element of
force, fraud, deceit, duress . . . or coercion
. . . ." has been widely interpreted as
excluding prisoners from research since
incarceration is a necessarily coercive con-
dition. However, in the U.S., the prevalent
opinion in the medical community,
endorsed by the American Medical
Association, was that the Nuremberg Code
pertained to Nazi atrocities, but not to the
increasingly prevalent medical experiments
being conducted using inmates in state and
federal jurisdictions. In fact, the post-war
flourishing of medical experimentation with-
in the U.S. penal system was being driven
by increased federal funding to investigate
medical illness, the formation of academic-
pharmaceutical alliances, and the need to
test various products in human subjects to
meet U.S. Food and Drug Administration
regulations.1,2,3,4
Prisoners were enlisted in a broad range of
clinical studies and the inclusion of inmates
in investigation became routine. In
Holmesburg Prison, a county facility in
Philadelphia, in the late 1960’s inmates
were recruited to participate in studies that
explored everything from simple detergents
and diet drinks to retinoic acid, dioxin, and
chemical warfare agents. The list of spon-
sors of these investigations included not
only pharmaceutical companies and other
corporations such as Dow Chemical, but
also the U.S. Army. However, in the early
1970's the public conscious shifted and
began to look unfavorably upon research
conducted in prisons. This change was
influenced by well-publicized revelations of
the serious side effects associated with
medications, such as birth defects caused
by the tranquilizer thalidomide and the
Tuskeegee syphilis experiments, which
were not conducted using inmates, but did
involve another vulnerable population:
black men in the U.S. rural south. By the
late 1970’s, legislation had been passed
preventing federal inmates from participat-
ing in clinical trials and very few state juris-
dictions continued their clinical research
programs using inmates.  
THE BELMONT REPORT AND
45 CFR 46
In response to the growing public concern
regarding abuses during clinical research,
the National Research Act was signed into
law on July 12, 1974.  This federal law cre-
ated the National Commission for the
Protection of Human Subjects of
Biomedical and Behavioral Research,
hereafter referred to as "The Commission".
One of The Commission's charges was to
identify the basic ethical principles that
should underlie the conduct of biomedical
and behavioral research involving human
subjects and to develop guidelines, which
should be followed to assure that such
research is conducted in accordance with
those principles. The Belmont Report
resulted from an intensive four-day period
of discussions held at the Smithsonian
Institution's Belmont Conference Center
supplemented by monthly deliberations of
The Commission held over a four-year peri-
od. It was published in The Code of Federal
Regulations (CFR), commonly called the
federal register or common rule, on April
18, 1979 as a statement of the Department
of Health, Education, and Welfare's policy
of ethical principles and guidelines for the
protection of human subjects of research.
Later this department evolved into the
Department of Health and Human Services
(DHHS) which remains responsible for the
protection of human subjects involved in
biomedical research through the Office of
Human Research Protection (OHRP). The
three basic principles that were detailed in
this report were respect for persons, benef-
icence, and justice. Respect for persons
has two important components:  individuals
should be treated as autonomous agents
and those with diminished autonomy are
entitled to protection. The report itself
directly addresses the issue of prisoner
participation in research:
"[R]espect for persons demands that sub-
jects enter into the research voluntarily and
with adequate information… In some situa-
tions, however, application of the principle
is not obvious. The involvement of prison-
ers as subjects of research provides an
instructive example. On the one hand, it
would seem that the principle of respect for
persons requires that prisoners not be
deprived of the opportunity to volunteer for
research. On the other hand, under prison
conditions they may be subtly coerced or
unduly influenced to engage in research
activities, for which they would not other-
wise volunteer…. Respect for persons
would then dictate that prisoners be pro-
tected. Whether to allow prisoners to "vol-
unteer" or to "protect" them presents a
dilemma."  
These passages accurately state the
equipoise that persists to this day regarding
prisoners as research subjects. How to
best balance between not "depriving" the
inmate of an opportunity to participate and
protecting the inmate from coercion
remains the enduring challenge of this
issue with vocal advocates of each position
weighing in.
The federal legislation, published in the
Code of Federal Regulations, that deals
with the protection of human research sub-
jects is called Title 45 CFR Part 46 and is
commonly referred to as 45 CFR 46. It
became law in 1978, was revised in 2001
and provides some guidance regarding the
inclusion of prisoners in research.  45 CFR
46 applies to all research involving human
subjects that is conducted, supported by, or
otherwise subject to regulation by any fed-
eral department or agency. It provides
direction on how agencies and institutions
can file letters of assurance that they will
comply with these regulations, direction on
the composition and duties of institutional
review boards (IRBs) that oversee federal-
ly funded research, requirements for
informed consent, and documentation of
informed consent. Subpart B of this law
lists additional protections for pregnant
women, human fetuses, and neonates, and
Subpart C lists additional DHHS protec-
tions pertaining to biomedical and behav-
ioral research involving prisoners as sub-
jects (6 45 CFR 46).
The additional protections of Subpart C
provide for prisoners that participate in bio-
medical research including: 1. Inclusion of
a prisoner or a prisoner representative on
the IRB reviewing the research; 2.
Assigning additional duties to the reviewing
IRB to be sure that the research is permis-
sible, free of undue influence, safe, acces-
sible and fair to all inmates, presented in
understandable language, and does not
have any effect on parole. Permissible
research involving prisoners includes: "(A)
study of the possible causes, effects, and
processes of incarceration, and of criminal
behavior, provided that the study presents
no more than minimal risk and no more
than inconvenience to the subjects; (B)
study of prisons as institutional structures
r of prisoners as incarcerated persons,
provided that the study presents no more
than minimal risk and no more than incon-
venience to the subjects; (C) research on
conditions particularly affecting prisoners
as a class (for example, vaccine trials and
other research on hepatitis which is much
more prevalent in prisons than elsewhere;
and research on social and psychological
problems such as alcoholism, drug addic-
tion, and sexual assaults) provided that the
study may proceed only after the  Secretary
[of the Department of Health and Human
Services] has consulted with appropriate
experts including experts in penology, med-
icine, and ethics, and published notice, in
the Federal Register, of his intent to
approve such research; or (D) research on
practices, both innovative and accepted,
which have the intent and reasonable prob-
ability of improving the health or well-being
of the subject.  In cases in which those
studies require the assignment of prisoners
in a manner consistent with protocols
approved by the IRB to control groups
which may not benefit from the research,
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3the study may proceed only after the
Secretary has consulted with appropriate
experts, including experts in penology,
medicine, and ethics, and published notice
in the Federal Register, of the intent to
approve such research."6
According to 45 CFR 46, permissible
research includes not only social, behav-
ioral, and psychological research, but also
therapeutic trials using pharmaceutical
agents for medical conditions that particu-
larly affect inmates (though the use of
placebos in this situation requires addition-
al safeguards.) The example given in the
law specifically mentions hepatitis, but the
health condition that came to the forefront
as a condition particularly affecting prison-
ers was HIV infection and AIDS. Under
pressure from patients and patient advoca-
cy groups, HIV clinical research moved
from the strictly academic setting to a vari-
ety of other patient sites including non-uni-
versity affiliated hospitals, private physician
offices, and community consortiums.  In the
1990s, when effective HIV treatment thera-
pies were under investigation in multiple
clinical trials, HIV clinical trials at some aca-
demic sites re-entered the prison setting.
In this case, inclusion of prisoners was
often justified as a means to provide access
to cutting-edge therapies to persons living
with HIV who were incarcerated.  At sever-
al major medical centers, HIV research was
extended into correctional facilities. For
example, clinical trials being conducted at
The University of Texas Medical Branch in
Galveston and the University of Miami in
Florida were offered to inmates in the Texas
Department of Criminal Justice and the
Florida Department of Corrections, respec-
tively.  Additionally, behavioral research
regarding AIDS in the incarcerated popula-
tion were being conducted by Yale and
Brown Universities in their respective state
jurisdictions.  Not all of these studies fell
under the purview of 45 CFR 46, as these
regulations apply to federally funded stud-
ies and some of these investigations were
funded by pharmaceutical industry support.
Allowing prisoners to participate seemed
appropriate since life-saving treatment, not
available outside of clinical trials, became
available to incarcerated patients with
AIDS.  
In 1998, one of the pharmaceutical manu-
facturers of HIV medications implemented
a non-comparative trial of a combination of
three nucleosides for the treatment of HIV
in prisoners only.  Many prisoner advocates
became concerned that prisoners were
being exploited in the name of medical
research since all of the pharmaceutical
agents in this trial were available outside of
clinical trials and there was already some
question in 1998 if three nucleosides alone
were adequate therapy for HIV infection.7
Today we know that triple nucleoside thera-
py is inferior to either protease inhibitor-
based or non-nucleoside reverse transcrip-
tase inhibitor-based potent combination
therapy and is not recommended as first
line therapy for HIV infection.  Subjecting
prisoners to the choice of receiving what
might be inferior treatment seemed to
exceed the limit of minimal risk that 45 CFR
46 had set as a standard.  The scientific
research community was again faced with
the difficult question of how best to protect
prisoners. 
As a result, a group of concerned correc-
tional clinicians organized a conference,
"Clinical Trials in Corrections." Over 100
like-minded individuals and representatives
from the Office of Human Research
Protections attended this meeting, and pro-
ceeds were published in 2001 in AIDS
Reader.13 What happened next had a chill-
ing effect on pharmaceutical medical
research using prisoners as subjects. The
IRBs at the University of Texas Medical
Branch, the University of Miami, Brown
University, and Yale University were
reviewed by the OHRP and received "let-
ters of determination"8 that the composition
of the IRBs and their procedures to ensure
the protection of prisoners were inade-
quate.  Enrollment in clinic trials was sus-
pended at the University of Texas Medical
Branch at Galveston9 and the University of
Miami.10 Although each of the Universities
cited above eventually received permission
to resume research with prisoners, virtually
no clinical trials using pharmaceutical
agents are being conducted in the state
prison systems today.  Behavioral, social,
and psychological research continues to be
pursued by many institutions using prison-
ers as subjects.
COMMENT 
It has now been over 30 years since 45
CFR 46 Subpart C has been enacted.
Whether an inmate can ever act
autonomously and what the standard of
minimal risk for an inmate remains
unclear.11 Three issues are at the crux of
this question. First, are prisoners and the
general population well served by not hav-
ing federal funding for clinical research
using pharmaceutical therapies in the
incarcerated population; second, does the
law serve its goal to protect a vulnerable
population; and third, does the federal law
impact upon non-federally funded
research?  Secretary Tommy Thompson of
the DHHS has speculated that it is past
time that Subpart C be evaluated again
(personal communication).  To this end, the
DHHS has asked the Institute of Medicine
of the National Academy of Sciences to
investigate the impact of Subpart C, and to
determine if there should be any change in
the current law. The Committee of Ethical
Considerations for Revisions to the DHHS'
Regulations for Protection of Prisoners
Involved in Research was impaneled and
will examine whether the conclusions
reached by the National Commission for
the Protection of Human Subjects of
Biomedical and Behavioral Research in the
1970’s remain appropriate today.12 The
committee will hold five public meetings at
which they will collect data from invited
panelists who work or perform research in
the correctional setting and will also hold
two workshops to further inform the
process.  Three of the public meetings have
been held: March 16, 2005, National
Academies of Science, Washington, D.C.,
May 4, 2005, The National Academies of
Science, Washington, D.C., and July 18,
the Gladstone Institute, San Francisco, CA.
The committee's final report is expected in
March, 2006.
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Dear Colleagues, 
This issue is dedicated to clinical trials in corrections. Prior to 2000, several correctional practi-
tioners and facilities were involved in clinical trials in order to permit the incarcerated population t
gain the benefits of investigational drugs and other therapies that could only be obtained t rough
trials. In 2000, the Office of Protection from Research Risks (currently named Office for Human
Research Protections) investigated every clinical trial from every major university, correctional sys-
tem, and quality Institutional Review Board involved in prisoner research. That investigation
caused most of the aforementioned programs to stop enrolling new patients and taper their exist-
ing efforts. 
Many of us involved in correctional healthcare felt that both society and our patients were
inadequately served by this act. Although mostly minor violations were documented, the tone cre-
ated by the investigation lead to irreparable damage to clinical trials in corrections. Universities
decided it was not worth the effort and correctional administrators wanted no part of any potential
controversy.  
The advantages of clinical trials in correctional populations, both for the inmates and society, and
the advocacy for them, are phenomenal.  There was a pervasive feeling that affording this benefit
to our patients was going to be impossible, even though many of us continually brought the issue
of clinical trials in corrections to the highest levels of authority. 
In the last year of his position as Agency Head of the Department of Health and Human Services
(DHHS), Secretary Tommy Thompson personally determined that there might be real value to
inmates and society if the question of clinical trials within clinical settings were evaluated again. To
that end, the DHHS asked the Institute of Medicine of the National Academy of Sciences to reeval-
uate the pertinent parts of Federal law pertaining to prisoner inclusion in research. 
It should be our job to advocate for our patients in this area and to remind the committee of two
specific items: first - the effect of Federal law is far more reaching than the words of the statute
themselves and, second - the current situation discriminates against legitimate scientific inquiry
and encourages unregulated research which may be performed solely for remuneration. 
After reading this issue, readers should be familiar with the history of research involving prisoners,
45 CFR 46, the  Belmont Report and the requirements for conducting research involving prisoners.
Readers should also be able to identify when research requires approval by an Institutional Review
Board. 
Very truly yours,
David Thomas*, MD
*Nothing to Disclose
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Are the specimens/data obtained from living individuals?
NO, individuals are NOT living YES, individuals ARE living
Are the specimens/data:
Unidentifiable specimens/data obtained from a commercial provider
OR
Unidentifiable specimens/data obtained from a provider that is prohibited from
releasing identifiers by established regulations/policies
NOT Human Subjects Research
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NO
Were/will the specimens/data be collected specifically for the proposed
research through an interaction or intervention with living individuals?
NO
Can the recipient link the specimens/data directly 
to identifiable living individuals?
YES
Human Subjects Research
YES
Human Subjects Research
NO
Can the provider link the specimens/data, directly or
indirectly, to identifiable living individuals?
YES
Human Subjects Research
YES
Does the provider meet the definition of an "investigator" in the 
recipient's research
NO
NOT Human Subjects Research
YES
YES, provider is collaborating in recipient's research
NO
NO, provider is "solely providing”
Are the specimens/data provided with a code link-
ing them to identifiable living individuals?
YES
Can the recipient readily ascertain the identities of the individuals
studies research to whom the specimens/data pertain?**
NO
NOT Human Subjects Research
YES
Human Subjects Research*
NO
NOT Human Subjects Research
Human Subjects Research*
IDCR-o-gram continued on page 6
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Footnotes
*All human subjects research must obtain institutional review
board (IRB) approval.  Exceptions include when there is no effort
to contribute to the general body of knowledge and the informa-
tion will be used only for risk management or internal modifica-
tions of ones' own system or facility.
All DHHS-supported human subjects research involving prisoners
as subjects must comply with all regulations set forth in 45 CFR
46 Subpart C.  When prisoners are involved as subjects in
research, composition of the IRB must satisfy the following
requirements:
- A majority of the IRB (exclusive of prisoner members) shall
have no association with the prison(s) involved, apart from their
membership on the IRB. 
- At least one member of the IRB must be a prisoner, or a prison-
er representative with appropriate background and experience to
serve in that capacity, except that where a particular research
project is reviewed by more than one IRB, only one IRB need
satisfy this requirement.
Research involving prisoners (or other vulnerable populations)
cannot receive expedited IRB approval.
** Examples of situations in which the recipient cannot link the
specimens/data to living individuals include:
- The key to deciper the code is destroyed before the research
begins
- The investigators and the holder of the key to the code enter
into an agreement preventing the release of the key to investiga-
tors under any circumstances
- There are IRB-approved written policies in place preventing
release of the key under any circumstances
- There are other legal requirements prohibiting the release of the
key under any circumstances
Endnotes
Adapted from Office of Extramural Research. Research involving
private information or biological specimens.  (n.d.).  Accessed
August 17, 2005 from
http://grants.nih.gov/grants/policy/hs/index.htm and
NIH. Office of Human Research Protections. Guidance on the
involvement of prisoners as research.  (n.d.). Accessed August
17, 2005 from http://www.hhs.gov/ohrp/humansubjects/guid-
ance/prisoner.htm
Of the state laws, only New York has specific requirements for prisoner research. States lacking specific requirements for prisoner
research must adhere to state provisions on research. Almost all states permit a researcher to opt out of the state statute if the
researcher is performing their research under a Federal-wide assurance and agrees to follow 45 CFR 46.
*CA Health & Saf. Code # 24171-24179.5 (2003) et. seq.
**Fl Stat. 381.85(2003) & 743.07 (2003).
***GA O.C.G.A. 33-24-59.1 (2002); & 39-1-1 (2003) & 360-121-01-05 (2003).
^KY 900 KAR 1:060 stat. 4(1)(a) (2003) & 920 KAR 1:060 ("Protection of Human Subjects") (2003).
^^MD Health Code Ann. Stat. 13-2001 and 2002 (2003). 
^^^NC Gen. Stat. 58-3-255 (2004).
oNY Public Health Law 2444(3) (2004).
STATE LAWS 101*
State
California*
Florida**
Georgia***
Kentucky^
Maryland^^, 
North Carolina^^^
Wisconsin,
Pennsylvania, Texas,
Ohio, Virginia
New Yorko
Legislation
Specific legislation including criminal penalties for failure to comply; requirement that all clinical investiga-
tors - no matter the source of funding - present to all human subjects a document known as the
"Experimental Subjects Bill of Rights," and comply with other parts of its extensive statue
Florida has its own Review Council for Humans Subjects, but this only applies to research performed in
Department of Health or Department of Children and Family facilities (or by contract with those agencies).
The correctional systems have no similar protective agency.
Georgia has specific restrictions on cancer and THC research and surgical procedures under investigation.
Kentucky has a Cabinet for Health Services, which has specific requirements for research funded through
the state.
Maryland and North Carolina have adopted the Federal statute for all state participants in research.
Wisconsin, Pennsylvania, Texas, Ohio, and Virginia have all adopted the basic precepts of the Federal
statute, but have made modifications by their legislatures. For instance, Ohio requires fully informed con-
sent even for proposals that have minimal risk.
New York has the most complex of the statutes, adopting both the Federal 45 CFR 46 and overlaying cer-
tain state requirements. Prisoner research requires the specific approval of the Commissioner of the
Department of Health. The New York statute directly attempts to limit single practitioners or small groups
from conducting clinical research by specifically requiring "All individuals seeking to conduct research must
affiliate themselves with an agency or institution that has…a human research review committee."
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7Research 101: Types of Clinical Trials
Type of Trial
Treatment Trials
Prevention Trials
Diagnostic Trials
Screening Trials
Quality of Life Trials
Purpose
Test experimental treatments, new combinations of drugs, or new approaches to surgery or radia-
tion therapy
Look for better ways to prevent disease in people who have never had the disease or to prevent
a disease from returning. These approaches may include medicines, vitamins, vaccines, miner-
als, or lifestyle changes.
Conducted to find better tests or procedures for diagnosing a particular disease or condition.
Test the best way to detect certain diseases or health conditions.
Explore ways to improve comfort and the quality of life for individuals with a chronic illness.
Description
Purpose
Number 
of People
Given Drug
Additional
Information
Phase I
Initial studies
Assess the safety,
tolerability, metab-
olism, and phar-
macologic actions
of the therapy in
humans and the
side effects asso-
ciated with
increasing doses
20-80
Conducted in
inpatient clinic,
where subject can
be observed by
full-time medical
staff; not blinded;
often no placebo
control
Phase II
Controlled clinical
studies
Evaluate clinical
efficacy of the
therapy for a par-
ticular indication
or indications in
patients with the
disease/condition
under study;
determine the
common short-
term side effects
and risks
100-300
The development
process for a new
therapy often fails
at this phase due
to the discovery of
poor efficacy or
toxic effects
Phase IV
Post-marketing
studies
Detect any rare or
long-term adverse
effects over a
much larger
patient population
and timescale
than was possible
during the initial
clinical trials;
delineate addition-
al information,
including drugs'
risks, benefits,
and optimal use
Varies
Phase IV studies
may be mandated
by regulatory
authorities or may
be undertaken by
the sponsoring
company for com-
petitive or other
reasons; adverse
effects detected
by Phase IV trials
may result in the
withdrawal or
restriction of a
therapy
Phase III
Expanded controlled and uncontrolled trials
after preliminary evidence of the drug has
been obtained
Gather additional information to evaluate the
overall benefit-risk relationship of the drug and
provide adequate basis for physician labeling;
definitively assesses efficacy of the new thera-
py, especially in comparison with currently
available alternatives
1,000-3,000
Double-blind randomized controlled trials;
most expensive, time-consuming phase to
design and run; once a therapy has proven
satisfactory over Phase III trials, the trial
results are usually combined into a large docu-
ment containing a comprehensive description
of the methods and results of human and ani-
mal studies, manufacturing procedures, formu-
lation details, and shelf life. This collection of
information is then submitted to the FDA for
approval of the therapy.
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Clinical Trial Phases*
*All clinical trials are conducted in phases.
Tables adapted from: National Institutes of Health.  Clinical Trials information.  (n.d.).  Accessed August 3, 2005 from 
http://www.clinicaltrials.gov/ct/info/whatis
United States Conference on
AIDS
September 28-October 2, 2005
Houston, Texas
Visit: www.nmac.org
IDSA Conference
October 6-9, 2005
San Francisco, CA
Visit: www.idsociety.org
National Conference on
Correctional Health Care
(NCCHC)
October 8-12, 2005
Denver, Colorado
Visit: www.ncchc.org
IDCR Pre-Conference Seminar
at NCCHC
"Infectious Diseases in
Corrections: An Integrated
Approach"
October 8, 2005
Denver, Colorado
Visit: www.ncchc.org 
Society of Correctional
Physicians Annual Meeting
October 9, 2005
Denver, Colorado
Visit: www.corrdocs.org
"Drug-drug Interactions and
Metabolic Complications of
HIV"
Satellite Broadcast
October 26, 2005
12:30-2:30pm EST
Visit:
www.amc.edu/patient/hiv/hivconf/
index.htm
APHA Meeting and Exposition
November 5-9, 2005
New Orleans, LA
Visit:  www.apha.org
American Association for the
Study of Liver Diseases
Meeting
November 11-15, 2005
San Francisco, CA
Visit: www.aasld.org
National Viral Hepatitis
Prevention Conference
December 5-9
Washington, DC
Visit: www.cdc.gov/ncidod/
diseases/hepatitis.conference.htm
XVI International AIDS
Conference 
August 13-18, 2006
Toronto, Canada 
Visit: www.aids2006.org
SAVE THE
DATES
8
24 vs 48 Weeks Pegasys/RBV for Co-infec-
tion: Which is Better?
In a randomized, controlled trial, 128 patients co-
infected with HIV and HCV genotype 2 or 3
received 180 mcg Pegasys sq once weekly in
combination with 10.6-13.0 mg/kg/day ribavirin
(RBV.)  All patients with undetectable HCV RNA
at 24 weeks after initiation of therapy were ran-
domized at 28 weeks to either stop treatment or
continue treatment for 20 weeks, for a total of 48
weeks of treatment.  A significantly lower relapse
rate was found in the patient group receiving 48
weeks of treatment compared to those receiving
24 weeks of treatment (11% vs 40%.)  Study
authors concluded that the optimal duration of
treatment in HCV genotype 2- and 3-infected
patients co-infected with HIV is at least 48 weeks.
Zanini, Puoti, et al.  Poster abstract
MoPpLB0103.  International AIDS Conference.
Rio de Janeiro.  July 25, 2005.
Texas Mandates HIV Testing for All Inmates
Texas Governor Rick Perry signed legislation on
June 21 implementing mandatory HIV testing for
inmates pending release from Texas' prisons.
The policy will be adopted in the Texas
Department of Criminal Justice by September 1,
with the hope of preventing the spread of the
virus both within and outside of the Texas prison
system and to inform inmates of their HIV status.
The University of Texas Medical Brach at
Galveston, which administers healthcare to the
majority of Texas' correctional facilities, recently
reported that HIV prevalence within the Texas
prison system is 2.1%.  
West M.  Daily Texan.  Accessed June 21, 2005
from www.dailytexanonline.com/
media/paper410/news/2005/06/21/University/In
mates.To.Take.Hiv.Test.Before.Release-
958334.shtml.
Updates to the Guidelines for Use of ARVs in
HIV-1-Infected Adults/Adolescents
The Panel on Clinical Practices for the Treatment
of HIV Infection has issued the following supple-
mental recommendations, effective immediately,
for the use of antiretroviral agents (ARVs) in HIV-
1-infected adults and adolescents: (1) a regimen
containing "tenofovir + didanosine + NNRTI"
should not be used as an initial regimen in ARV
treatment-naïve patients and (2) lopinavir/riton-
avir can be dosed as one single daily dose (6
capsules or 10mL - equivalent to 800mg
lopinavir/200mg ritonavir) in treatment-naïve
patients.  Once-daily dosing is not recommended
in treatment-experienced patients or in patients
eceiving concomitant efavirenz, nevirapine,
amprenavir, fosamprenavir or nelfinavir.
NIH. Antiretroviral treatment guidelines.  (n.d.).
Accessed August 15, 2005 from
http://aidsinfo.nih.gov/guidelines/default_db2.asp
?id=50
Pancreatitis in HIV-Infected Adults
In a cross-protocol analysis of 20 Adult AIDS
Clinical Trials Group (AACTG) study sites, rates
of clinical and clinical/laboratory pancreatitis were
relatively low.  Seventeen of the 20 studies con-
sidered two definitions of pancreatitis: clinical
pancreatitis and a combined definition of clinical
and/or laboratory pancreatitis, defined as grade 3
r 4 amylase and/or lipase elevation. The remain-
ing three studies defined pancreatitis as elevated
serum amylase and a compatible clinical syn-
drome of nausea, vomiting and/or abdominal
pain. Pancreatitis incident rates were calculated
based on a Poisson distribution.  Analysis of 17
tudies reflecting 4 arms yielded a relatively low
overall clinical pancreatitis rate of 0.61 per 100
person-years (PYs) and a higher clinical/labora-
ory pancreatitis rate of 2.23 per 100 PYs. Thus,
the clinical/laboratory pancreatitis definition yield-
ed a rate nearly four-fold higher than the clinical
pancreatitis definition. Rates of pancreatitis in
didanosine (ddI) arms seemed to be dose depen-
dent.  Pancreatitis rates for ddI/stavudine (d4T)
trials were high at 4.16 per 100 PYs clinical and
6.25 per 100 PYs clinical/laboratory.  The highest
rates were seen with the combination
indinavir/ddI/d4T.  Study authors concluded that
the combination of nucleoside reverse transcrip-
tase inhibitors (NRTIs) and definition of pancre-
atitis has an impact on the incidence of pancre-
atitis.  Further evaluation is needed to determine
how much of this pancreatitis is directly caused
by antiretroviral drugs and how much is attribut-
able to preexisting comorbidities.
Reisler R, et al.  JAIDS.  2005; 39(2):159-66.
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RESOURCES
NIH Clinical Trials Website
http://www.clinicaltrials.gov/ct/info/whatis
NIH Office of Extramural Research Human Subjects Website
http://grants.nih.gov/grants/policy/hs/index.htm
DHHS Office for Human Research Protections (OHRP)
http://www.hhs.gov/ohrp/
DHHS OHRP Guidance on the Involvement of Prisoners in Research 
http://www.hhs.gov/ohrp/humansubjects/guidance/prisoner.htm
The Belmont Report.  Full report available at:
http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.htm
OHRP Human Subject Assurance Online Training
http://ohrp-ed.od.nih.gov/CBTs/Assurance/login.asp
SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through February 28, 2006. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  The following research examples are subject to IRB approval:
A. DHHS-supported research involving prisoners.
B. Research involving prisoners in which the information is 
used solely for internal modifications of one's own 
system/facility.
C. Research that involves prisoners, in which data may 
indirectly be linked to identifiable participants of the study.
D. A and B
E. A and C
2.  The following statement(s) regarding clinical trial phases
is/are false:
A. Phase II clinical trials are conducted to determine the 
short- and long-term side effects and risks of a new 
therapy/drug.
B. Phase III clinical trials typically involve 300-3,000 
participants.
C. Phase I clinical trials assess the metabolism and safety of 
a therapy/drug and are blinded, controlled studies.
D. None of the above statements are false.
E. All of the above statements are false.
3.  A prisoner or prisoner representative should be included on
the IRB reviewing research involving prisoners, but is not neces-
sary if a therapy/drug is not being given to prisoners during the
study.  True or false?
A. True
B. False
4.  According to 45 CFR 46, permissible research involving pris-
oners includes the following:
A. The study of prisons as institutional entities, providing that 
the research does not present a high risk to the subjects.
B. The study or prisoners as incarcerated persons, providing 
that the research does not present a high risk to the 
subjects.
C. Research which has the intent of improving the health of 
the subject.
D. None of the above research is permissible under 
45 CFR 46.
E. All of the above research is permissible under 45 CFR 46.
5.  Research involving prisoners cannot received expedited IRB
approval.  True or false?
A. True
B. False
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IDCR EVALUATION
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
In the News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that IDCR helps you in your work?
Why or why not?
3. What future topics should IDCR address?
4. How can IDCR be made more useful to you?
5. Do you have specific comments on this issue?
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